Overview

A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest

Status:
Completed
Trial end date:
1997-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of two doses of intravenous NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart) versus placebo in the treatment of patients with symptomatic, decompressed congestive heart failure (CHF).
Phase:
Phase 3
Details
Lead Sponsor:
Scios, Inc.
Treatments:
Natriuretic Peptide, Brain